Nektar Therapeutics Annual Income Statement (NASDAQ:NKTR)

Add to My Stocks
$19.39 $0.53 (2.81%) NKTR stock closing price Apr 25, 2017 (Closing)

Looking at financial statements, along with the Nektar Therapeutics stock price, it's management, its economic moat, and industry competitors forms an important part of fundamental analysis.   An income statement is one of the three key financial statements furnished by a company, the other two being the balance sheet and the cashflow statement. The income statement is always for an accounting period, typically for a year or quarter, and affects the stock. In this case, the NKTR stock is bound to reflect the impact of the YoY decline of $65.35M. One also needs to look at Nektar Therapeutics assets, operating expenses and Nektar Therapeutics free cash flow. The profit and loss statement shows revenue of $165.43M for 2016. Revenue has decreased by $65.35M YoY for NKTR stock. Nektar Therapeutics revenue for 2016 is $165.43M. View revenue and profit details for latest and last 10 financial years.

show more
Annual
Quarterly
View Previous Years
View Next Years
Fiscal year is Jan - Dec. 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
Nektar Therapeutics Net Sales or Revenues
165.43M230.78M200.7M148.92M81.19M71.48M159.03M71.93M90.18M273.02M
Cost Of Goods Sold (COGS)30.21M34.1M28.53M38.5M30.42M21.89M25.66M30.94M35.03M147.51M
Nektar Therapeutics Gross Profit
135.22M196.68M172.17M110.41M50.76M49.58M133.37M40.98M55.14M125.51M
Research & Development Expense203.8M182.78M147.73M190.01M148.67M126.76M108.06M95.1M154.41M153.57M
Selling General & Admin Expense44.27M43.26M40.92M40.53M43.28M46.76M53.56M41M-16.61M56.33M
Income Before Depreciation Depletion Amortization-112.85M-29.37M-16.48M-120.13M-141.2M-123.93M-28.25M-95.13M-82.65M-84.4M
Depreciation Depletion Amortization---------0.94M
Non Operating Income2.38M-12.39M0.81M1.12M3.29M1.2M2.37M4.53M62.7M72.53M
Interest Expense42.18M38.9M38.75M40.76M33.54M10.22M11.17M12.17M15.19M18.63M
Nektar Therapeutics Pretax Income
-152.64M-80.67M-54.42M-159.76M-171.44M-132.96M-37.05M-102.77M-35.14M-31.45M
Provision for Income Taxes0.87M0.5M-0.51M2.24M0.4M1.01M0.88M-0.25M-0.8M1.3M
Minority Interest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-153.52M-81.17M-53.91M-162.01M-171.85M-133.97M-37.93M-102.51M-34.33M-32.76M
Extraordinary Items & Discontinued Operations----------
Nektar Therapeutics Net Income (Profit/Loss)
-153.52M-81.17M-53.91M-162.01M-171.85M-133.97M-37.93M-102.51M-34.33M-32.76M
Average Shares used to compute Diluted EPS139.6M132.46M126.87M115.73M114.82M112.94M94.08M92.77M92.41M91.88M
Average Shares used to compute Basic EPS139.6M132.46M126.87M115.73M114.82M112.94M94.08M92.77M92.41M91.88M
Income Before Nonrecurring Items-153.52M-81.18M-53.92M-162.01M-170.77M-133.98M-25.71M-102.52M-154.01M-83.29M
Income from Nonrecurring Items-----1.09M--12.23M-69.57M50.53M
Nektar Therapeutics Earnings Per Share Basic Net
-1.10-0.61-0.42-1.40-1.50-1.19-0.40-1.11-0.37-0.36
Nektar Therapeutics Earnings Per Share Diluted Net
-1.10-0.61-0.42-1.40-1.50-1.19-0.40-1.11-0.37-0.36
EPS Diluted Before Nonrecurring Items-1.10-0.61-0.42-1.40-1.49-1.19-0.27-1.11-1.67-0.91
Preferred Dividends Acc Pd----------
Dividends Common----------
Dividend Per Share Common----------
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years
Get Income statement for another ticker

1:22
NKTR
It is very helpful to read a report on Nektar Therapeutics stock analysis. An investor must check the following items in an income statement:
  • Revenue: This is the inflow that is generated from the sale of goods or services and is $165.43M for this year of 2016. Our Nektar Therapeutics revenue chart gives a clear visual representation of how the topline growth has been. Investors often invest in only those companies where the revenue is growing at a steady rate.
  • Bottom line: The Bottomline or the net income figure is arrived at by deducting all expenses from the topline which in this case is $165.43M - other expenses = $-153.52M for NKTR stock. An improving bottomline implies that the company is growing profits.
The income statement is also called statement of revenue and expense. The financials along with Nektar Therapeutics historical stock prices provides a lot of details about the firm. .

Nektar Therapeutics Income Statement - Key Financial Ratios

PS ratio (
price sales ratio
)
17.4714
Operating margin
-85.8
Net profit margin
-112.7
Dividend yield
0%